CME credits: 0.25

Valid until: 08-05-2020

Claim your CME credit at https://reachmd.com/programs/cme/clinical-considerations-in-treatment-sequencing-for-mcrc/10776/

Selecting optimal therapy for patients with mCRC after first-line failure can often best be informed by identifying the current driver oncogenes specific to each individual’s cancer. Such an approach can provide a more nuanced selection of chemotherapy (CT) and biologic combinations in second- and subsequent lines, including guidance for switching or continuing with a particular CT or biologic agent.

So how can you implement this approach in your practice? Dr. Alfredo Falcone is joined by Drs. Sebastian Stintzing and Tianshu Liu to share insights.